Changes in use of acute and preventive medications for migraine after erenumab initiation over 12 months: A United States retrospective cohort study
In this long-term study, we observed the discontinuation of both acute and preventive medications for migraine post-erenumab initiation.
Authors
- Andrew S. Park (ORCID: https://orcid.org/0000-0001-5188-4705)
- Jasjit K. Multani
- Kevin Hawkins (ORCID: https://orcid.org/0000-0002-2912-8038)
- Robert Urman (ORCID: https://orcid.org/0000-0003-2941-8964)
- Karminder Gill
- Mark Bensink (ORCID: https://orcid.org/0000-0002-5940-7898)
- Christopher Rhyne (ORCID: https://orcid.org/0000-0002-4540-4485)
- Karen M. Stockl (ORCID: https://orcid.org/0009-0007-9912-0211)
- Fiston Vuvu
- Kainan Sun
- Leah B. Patel
Institutions
- Amgen (United States) (US)
- Diamond Headache Clinic (US)
- IQVIA (United States) (US)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1111/head.14820
- Citations
- 3
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.16